For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 2,929,983 | |||
| Selling, general and administrative (including related party amounts of 645,250 and 0, respectively) | 4,843,615 | |||
| Total operating expenses | 7,773,598 | |||
| Loss from operations | -7,773,598 | |||
| Interest income | 215,041 | |||
| Net loss | -7,558,557 | |||
| Basic EPS | -8.16 | |||
| Diluted EPS | -8.16 | |||
| Basic Average Shares | 926,192 | |||
| Diluted Average Shares | 926,192 | |||
Dermata Therapeutics, Inc. (DRMAW)
Dermata Therapeutics, Inc. (DRMAW)